Loading...
•
Mar 31
REGENXBIO Q1 2025 Earnings Report
REGENXBIO posted strong revenue growth and returned to profitability in Q1 2025 driven by partnership-related income.
Key Takeaways
REGENXBIO reported $89.0 million in revenue and a net income of $6.1 million for Q1 2025, reversing last year’s net loss due to a $71.8 million boost from a licensing deal with Nippon Shinyaku.
Revenue surged to $89.0 million, primarily due to license and service revenue from the Nippon Shinyaku collaboration.
Net income reached $6.1 million compared to a $63.3 million net loss in Q1 2024.
R&D expenses slightly declined while G&A expenses rose due to increased personnel and service costs.
Cash and securities position strengthened to $272.7 million, expected to fund operations into H2 2026.
REGENXBIO
REGENXBIO
REGENXBIO Revenue by Segment
Revenue by Segment
License and Royalty Rev Revenue
CapyFin.comService Revenue
CapyFin.com Forward Guidance
REGENXBIO expects its current cash position to fund operations into the second half of 2026.
Positive Outlook
- Strong licensing revenue boosts financial position.
- Cash runway extended through H2 2026.
- Initiation of commercial manufacturing for RGX-202 planned for Q3 2025.
- FDA BLA acceptance for RGX-121 expected in May 2025.
- Advanced pivotal trial enrollments continue for multiple assets.
Challenges Ahead
- No updated financial projections for FY 2025 provided.
- Product revenue yet to commence, reliant on milestone payments.
- Increased G&A expenses could impact profitability.
- Significant portion of revenue is non-recurring from upfront payments.
- Clinical and regulatory milestones carry execution risks.